Inventage Lab Inc. Logo

Inventage Lab Inc.

Biopharmaceutical company developing advanced drug delivery systems.

389470 | KO

Overview

Corporate Details

ISIN(s):
KR7389470006
LEI:
Country:
South Korea
Address:
경기도 성남시 중원구 둔촌대로388번길 24, 101호, 601호, 612호, 성남시

Description

Inventage Lab Inc. is a biopharmaceutical company specializing in the development of advanced Drug Delivery Systems (DDS). The company's foundation is its proprietary microfluidics-based platform technology, Laminar-FluiDigm™, which is applied to pharmaceutical research and manufacturing. Inventage Lab operates two primary platforms: IVL-DrugFluidic® for developing and producing microsphere-based long-acting injectables, and IVL-GeneFluidic® for the formulation and manufacturing of Lipid Nanoparticles (LNPs) for nucleic acid and gene therapies. The company's pipeline is focused on treating chronic and refractory diseases, with key programs targeting androgenic alopecia (male pattern baldness) and Alzheimer's disease. Other development areas include drug re-discovery for conditions like rheumatic arthritis and multiple sclerosis, and collaborative projects for HIV treatments and mRNA-based therapies.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-03-14 00:00
주주총회소집공고
Korean 133.1 KB
2025-03-14 00:00
주주총회소집결의
Korean 10.8 KB
2025-03-14 00:00
[기재정정]주주총회소집공고
Korean 139.7 KB
2025-03-14 00:00
[기재정정]주주총회소집공고
Korean 139.8 KB
2025-03-12 00:00
증권발행결과(자율공시) (제3자배정 유상증자)
Korean 5.6 KB
2025-01-31 00:00
타법인주식및출자증권취득결정
Korean 25.1 KB
2025-01-31 00:00
주권관련사채권의취득결정
Korean 36.2 KB
2025-01-15 00:00
증권발행결과(자율공시) (제3회차 CB)
Korean 5.6 KB
2025-01-13 00:00
주요사항보고서(전환사채권발행결정)
Korean 75.9 KB
2025-01-13 00:00
주요사항보고서(유상증자결정)
Korean 32.9 KB
2024-12-13 00:00
임원ㆍ주요주주특정증권등소유상황보고서
Korean 21.5 KB
2024-12-13 00:00
주주명부폐쇄기간또는기준일설정
Korean 4.3 KB
2024-12-10 00:00
임원ㆍ주요주주특정증권등소유상황보고서
Korean 22.2 KB
2024-11-28 00:00
주식등의대량보유상황보고서(일반)
Korean 163.1 KB
2024-11-14 00:00
분기보고서 (2024.09)
Korean 1.1 MB

Automate Your Workflow. Get a real-time feed of all Inventage Lab Inc. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Inventage Lab Inc.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Inventage Lab Inc. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

1NKEMIA Logo
Biotechnology company providing R&D and services for the life sciences sector.
Spain
IKM
2cureX AB Logo
Develops an IVD test using 3D tumoroids to predict patient response to cancer drugs.
Sweden
2CUREX
Abera Bioscience AB Logo
Develops mucosal vaccines using a proprietary Outer Membrane Vesicle (OMV) platform.
Sweden
ABERA
Clinical-stage biopharma developing therapeutics for oncology and viral diseases.
South Korea
203400
ABL Bio Inc. Logo
Develops bispecific antibody therapeutics for oncology and neurodegenerative diseases.
South Korea
298380
Abpro Holdings, Inc. Logo
Clinical-stage biotech developing antibody therapeutics for oncology and ophthalmology.
United States of America
ABP
Absci Corp Logo
A generative AI drug creation company developing biologic medicines.
United States of America
ABSI
Achiko AG Logo
A digital services platform for cross-border business compliance and engagement.
Switzerland
ACHI
Active Biotech Logo
Biotechnology company developing drugs for oncology and inflammatory eye disorders.
Sweden
ACTI
Adagene Inc. Logo
Clinical-stage biotech developing antibody-based immunotherapies for oncology.
United States of America
ADAG

Report Sent!

Thank you. We will check the data and update it shortly.

Talk to a Data Expert

Have a question? We'll get back to you promptly.